Literature DB >> 31821965

Tissue distribution of naringin and derived metabolites in rats after a single oral administration.

Xuan Zeng1, Hongliang Yao2, Yuying Zheng1, Yudong He1, Yan He1, Hongyu Rao1, Peibo Li1, Weiwei Su3.   

Abstract

Naringin has been documented to possess multiple pharmacological activities. Reported pharmacokinetic studies revealed that oral bioavailability of naringin was low, in contrast to its significant pharmacological effects. The in vivo distribution of naringin and derived metabolites might partly explain this discrepancy. In this study, an ultra-fast liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry system (UFLC-Q-TOF-MS/MS) was used for profiling the distribution of naringin and its metabolites in rat plasma and fourteen tissues after oral administration. Naringin was widely distributed and its concentrations in certain tissues were much higher than that in plasma, especially in trachea and lung. Moreover, a total of 23 flavonoid metabolites and 15 phenolic catabolites were screened. Naringenin glucuronides were principal metabolites in plasma, while free naringenin and naringenin-7-O-sulfate were the major molecular forms in most tissues. Meanwhile, phenolic catabolites derived from naringin were found to be abundant in liver and kidney. These pharmacokinetic results would be useful to explain the pharmacodynamics of naringin.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Metabolites; Naringin; Rat; Tissue distribution; UFLC-Q-TOF-MS/MS

Mesh:

Substances:

Year:  2019        PMID: 31821965     DOI: 10.1016/j.jchromb.2019.121846

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

Review 1.  Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanisms.

Authors:  Yang Yang; Myah Trevethan; Shu Wang; Ling Zhao
Journal:  J Nutr Biochem       Date:  2022-02-18       Impact factor: 6.117

2.  Assessment of the feed additive consisting of naringin for all animal species for the renewal of its authorisation (HealthTech Bio Actives, S.L.U. (HTBA)).

Authors:  Vasileios Bampidis; Giovanna Azimonti; Maria de Lourdes Bastos; Henrik Christensen; Birgit Dusemund; Mojca Fašmon Durjava; Maryline Kouba; Marta López-Alonso; Secundino López Puente; Francesca Marcon; Baltasar Mayo; Alena Pechová; Mariana Petkova; Fernando Ramos; Yolanda Sanz; Roberto Edoardo Villa; Ruud Woutersen; Paul George Brantom; Johannes Westendorf; Jaume Galobart; Paola Manini; Fabiola Pizzo
Journal:  EFSA J       Date:  2022-04-22

3.  Development and Optimization of a High Sensitivity LC-MS/MS Method for the Determination of Hesperidin and Naringenin in Rat Plasma: Pharmacokinetic Approach.

Authors:  Jesús Alfredo Araujo-León; Rolffy Ortiz-Andrade; Rivelino Armando Vera-Sánchez; Julio Enrique Oney-Montalvo; Tania Isolina Coral-Martínez; Zulema Cantillo-Ciau
Journal:  Molecules       Date:  2020-09-16       Impact factor: 4.411

4.  A Rapid LC-MS/MS Method for Simultaneous Determination of Ten Flavonoid Metabolites of Naringin in Rat Urine and Its Application to an Excretion Study.

Authors:  Xuan Zeng; Yuying Zheng; Yan He; Wei Peng; Weiwei Su
Journal:  Foods       Date:  2022-01-24

Review 5.  Naringin and Naringenin: Their Mechanisms of Action and the Potential Anticancer Activities.

Authors:  Jolita Stabrauskiene; Dalia M Kopustinskiene; Robertas Lazauskas; Jurga Bernatoniene
Journal:  Biomedicines       Date:  2022-07-13

6.  A Pharmacokinetic Study of Mix-160 by LC-MS/MS: Oral Bioavailability of a Dosage Form of Citroflavonoids Mixture.

Authors:  Jesús Alfredo Araujo-León; Rolffy Ortiz-Andrade; Efrén Hernández-Baltazar; Emanuel Hernández-Núñez; Julio César Rivera-Leyva; Víctor Yáñez-Pérez; Priscila Vazquez-Garcia; Carla Georgina Cicero-Sarmiento; Juan Carlos Sánchez-Salgado; Maira Rubí Segura-Campos
Journal:  Molecules       Date:  2022-01-08       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.